Before we try a new product, we often search online or talk to other consumers to find out how well it works and if it lives up to manufacturer promises. We dig into its history and look for inconsistencies. Should we be any less vigilant when choosing a new medicine? In the U.K., lawmakers are demanding greater transparency from Big Pharma with regard to the results of clinical research and drug trials. The House of Commons Public Accounts Committee states that the methods and outcomes of tests should be available to the medical community and patients, so that they can.. READ MORE »
January 21, 2014
Pancreatic cancer is one of the most deadly silent killers. It is an aggressive disease with poor prognosis and limited treatment options, and is highly resistant to both chemotherapy and radiotherapy. Most patients develop symptoms after the cancer has spread to other organs, and the chance of survival drastically reduced. According to the Canadian Cancer Society, 4,700 Canadians will be diagnosed with pancreatic cancer this year – and 4,300 will die from it. More effective treatment methods are desperately needed to increase shockingly low survival rates. New clinical research from scientists at the Universities of Manchester and Michigan may provide.. READ MORE »
January 16, 2014
Over the last decade, foodies, environmentalists, animal rights advocates and health officials have spoken out about the dangers of “unnatural” foods. The excessive use of pesticides, the unhealthy – even deadly – side effects of hormone injected cattle, and the implications of genetically modified produce; all reasons many of us have gone organic, willing to spend extra on free-range and all-natural. Last year, cattle producers joined the chorus, taking aim at pharma giant Merck when its growth stimulant Zilmax allegedly caused disastrous side effects. Merck denies there is any clinical research to validate the claims and is currently strategizing a.. READ MORE »
January 14, 2014
Patients diagnose with recurrent glioblastoma multiforme (GBM), the most aggressive form of primary brain tumor, face a bleak survival rate of 3 to 9 months. Typically, patients are treated with surgery, chemotherapy and radiation – but these traditional techniques simply cannot keep up with an alarmingly fast rate of growth. GBM tumors are notoriously resistant to standard therapies, and remain one of the most dreaded diagnoses because despite treatment, they almost always come back. This is why clinical research in the field is so important, and why a new study from Northwestern Memorial Hospital is receiving positive attention. Using tumor.. READ MORE »
January 9, 2014
The global diabetes management market accounted for $41.9 billion in 2010, and is expected to rise to $114.3 billion by 2016. Even more staggering is the dramatic increase in those diagnosed; a figure that has risen by more than 373% over the last 30 years. Industry professionals and students in pharmaceutical courses have seen Big Pharma pursue innovative treatments for the disease, evolving from injections to inhalers and most recently, to new oral therapies. Johnson & Johnson and Bristol/AstraZeneca are the front runners in this race, having both recently released drugs that represent a brand new class of treatment for.. READ MORE »
January 7, 2014
We’re often told that washing our hands throughout the day will help to ward off germs, sickness and infection. And the best soap to use? Antibacterial, of course. However, according to the FDA, the very product we rely on to shield us from illness may well be making us sick. In a statement released on December 16, FDA officials warned consumers that the active ingredient in antibacterial soaps – triclosan – may be responsible for hormone imbalances and antibiotic resistance. In fact, despite its widespread use there is no clinical research to confirm that antibacterial soap has any added health.. READ MORE »
January 2, 2014
When our doctor prescribes a medicine, we assume the choice comes as a result of years of training and professional practice. We trust that the chosen drug is best suited to cure what ails us. However, pharma giant GlaxoSmithKline has recently found itself accused of interfering with that trust by offering doctors unethical compensation packages for promoting specific drugs. Rather than evaluating pertinent clinical research and considering both risks and benefits, doctors involved in the scheme are tempted by large bonuses to favor some therapies over others. Transparency with regard to drug promotion has long plagued the industry, but it.. READ MORE »
December 31, 2013
Is it possible to have too much of a good thing? With global challenges of poverty and scarcity, it’s hard to imagine governments thinking twice about embracing new sources of food supply. But that is exactly what is happening throughout the European Union (EU) this month with regard to farm animal cloning. The European Commission, the EU’s executive arm in Brussels is pushing for a ban on domestic animal cloning and any importation of cloned meat. EU Health Commissioner Tonio Borg describes the proposed regulation as “a ban on the technique, a ban on imports of the cloned animals themselves.. READ MORE »
December 26, 2013
Plummeting temperatures and icy sidewalks herald the arrival of flu season. More than just a runny nose and bothersome congestion, the flu assails its victims with fever, nausea, dizziness and restricted breathing. In some cases, influenza patients must be hospitalized, and statistics reveal that the very young and the elderly are the most vulnerable to serious – even deadly- complications. According to Canada’s Community and Hospital Infection Control Association, last year’s flu season affected more 31,000 people across the country. Last winter, 1 out of every 500 Americans over the age of 65 was hospitalized as a result of influenza. .. READ MORE »
December 24, 2013
Approximately 2.3 million people worldwide suffer from multiple sclerosis (MS). The disease develops when the nerves of the brain and the spinal cord are damaged by one’s own immune system. The ultimate result is paralysis, vision loss, and diminished brain function. Not only is MS physically and emotionally devastating, treatment comes with a hefty price tag. In the US, one year of therapy rings in at around $50,000. Bringing a ray of hope to MS sufferers, clinical research has revealed that a tuberculosis vaccine may help prevent the development of MS in patients with early symptoms. It’s an exciting alternative therapy for the.. READ MORE »
December 19, 2013